A Phase I/II Trial of Ibrutinib (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Mar 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 15 Nov 2018 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 21 Jul 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 21 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.